Journal
SCIENCE
Volume 292, Issue 5514, Pages 69-74Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.1058915
Keywords
-
Categories
Funding
- NCRR NIH HHS [P51 RR000165] Funding Source: Medline
- NIAID NIH HHS [P01 AI 43045] Funding Source: Medline
- NIDA NIH HHS [P30 DA 12121] Funding Source: Medline
Ask authors/readers for more resources
Heterologous prime/boost regimens have the potential for raising high Levels of immune responses. Here we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available